What Does Eyp Mean? the Story Behind Eyepoint's Duravyu Implant and Phase 3 Trial Results
By Marcus Vance
Headlines surrounding EYP shifted dramatically following the readout of the first Phase 3 wet AMD registration trial. Regulators design these pivotal trials around a rigorous non-inferiority margin: proving that the new drug preserves Best-Corrected Visual Acuity (BCVA) on the ETDRS eye chart just as effectively as standard 2 mg or 8 mg aflibercept administered every eight weeks.
EYP-1901 delivered on its main promise. Patients receiving DURAVYU on an extended, six-month maintenance cycle matched the visual gains seen in the aflibercept control arm, settling the core question of whether sustained tyrosine kinase inhibition could protect central vision. At the same time, the trial logged what industry analysts described as mixed anatomical endpoints. While visual acuity remained intact, measurements of central subfield thickness (CST) on optical coherence tomography (OCT) showed minor fluctuations in retinal dryness across certain subgroups.
| Clinical Parameter | EYP-1901 (DURAVYU Implant) | Aflibercept Control (Standard Care) |
|---|---|---|
| Visual Acuity (BCVA) | Achieved statistical non-inferiority; letter stability preserved | Baseline visual gain maintained on standard schedule |
| Dosing Interval | Every 6 months (single in-office insert) | Every 8 to 12 weeks (continuous maintenance) |
| Treatment Burden Drop | 70%, 85% reduction in supplemental injections | 0% (fixed high-frequency regimen) |
| Anatomic Drying (CST) | Mixed; slight variance in OCT retinal fluid resolution | Rapid, predictable fluid clearance |
| Target Patient Fit | Previously stabilized wet AMD; high clinic travel friction | Acute exudative flare-ups; newly diagnosed naive eyes |
The trial demonstrated that vorolanib keeps patients from losing letters on the chart, but doctors must balance that against retinal fluid control. When fluid persists without causing vision loss, clinicians refer to it as "tolerated residual fluid." Some practitioners welcome this trade-off if it frees patients from six injections a year; others prefer aggressive drying at all costs.
Marcus Vance is a cybersecurity auditor and technology writer dedicated to educating the public about online safety, data privacy regulations, enterprise security, and emerging cyber threats.
